ABSTRACT
Rhodococcus equi is a gram-positive facultative and intracellular pathogen and etiologic agent of equine rhodococcosis (QUINN et al., 1994) . The main clinical manifestation of rhodococcosis is pyogranulomatous bronchopneumonia in foals under six months of age (QUINN et al., 1994) . This disease is responsible for large economic losses due to mortality, since pneumonia is a major cause of death in foals (GIGUÈRE et al., 2011) . In vitro, R. equi has to be sensitive to a wide variety of antibiotics, such as aminoglycosides, beta-lactams and second-generation of cephalosporins (GIGUÈRE et al., 2010) . However, their ability to replicate in macrophages and neutrophils limited the therapeutic options to drugs able to penetrate in lipophilic environment (BUCKLEY et al., 2007) .
In 1980 the combination of erithromicyn (ERY) and rifampicin become the treatment of equine rhodococcosis highly efficient and dramatically reduced the mortality in foals (GIGUERE et al., 2010) . Since then, R. equi resistance to these drugs has been observed (BUCKLEY et al., 2007) . In this respect, azithromycin (AZM) and clarithromycin (CLR) have been proposed as alternatives to ERY for the treatment of R. equi infections in foals (JACKS et al., 2003) . Furthermore, when compared with ERY theses drugs are chemically more stable, possess greater bioavailability and achieve higher concentrations in macrophages and neutrophils (JACKS et al., 2003) . However, some studies have shown the emergence of strains resistant also to AZM and CLR. On the basis of the lack of data about Brazilian R. equi isolates, this study aimed to characterize the minimum inhibitory concentration (MIC) of AZM, CLR and ERY against 44 R. equi isolates from different sources.
R. equi were isolated from clinical (n=15), soil (n=15), feces (n=9) and installations (n=5) samples. All those were collected at equine breeding farms, located in Rio Grande do Sul state, Brazil, between 1991 and 2013 year. Clinical samples were isolated from postmortem lung lesions in foals, feces samples were collected from healthy mares, soil samples were taken from paddocks and installations samples were collected from wall stables, drinkers and feeders. All isolates were characterized as R. equi by phenotypic features (QUINN et al., 1994) , and then confirmed genotypically according to MONEGO et al. (2009) . All isolates remained lyophilized and stored at -20°C until time of testing. The MIC tests were performed in Müeller-Hinton broth (MHB) medium (Himedia ® Laboratories) using the microdilution method in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2013) . All microorganisms were cultured in MHB for 24h aerobically at 37°C. For each microorganism, an inoculum suspension was prepared in 0.9% saline, adjusted to the turbidity of 0.5 on the McFarland' scale, and absorbance readings were performed in a spectrophotometer at 600 nm-wavelength. These suspensions were diluted in MHB and approximately 1x10 5 CFU ml -1 were inoculated into the microtiter plates. The antimicrobials (AZM, CLR and ERY) were tested at 0.03 up 128µg ml -1 . The standard strain, R. equi ATCC 33701, known to be sensitive to AZM, CLR and ERY, was used as quality control tests (GIGUÈRE et al., 2010) . The MIC was defined as the lowest concentration of antimicrobials that inhibited the visible growth of R. equi isolates after overnight incubation evidenced by the addition of 20μL of 2,3,5-triphenyltetrazolium chloride (Vetec ® ) 1%. R. equi isolates were classified as sensitive (≤2µg ml -1 -AZM and CLR, and ≤0.5µg ml -1 -ERY) or resistant (≥8µg ml -1 -AZM, CLR and ERY) (CLSI, 2009). In addition, isolates with MIC values between the concentrations mentioned above were classified as intermediate sensitivity. All of the susceptibility tests were performed using at least three biological replicates and two technical replicates. The Kruskal-Wallis test was employed to calculate the association among antimicrobials MIC and the source of the isolates and the year of sample collection. The Bonferroni test was used to calculate the media when it was observed differences. The minimum significance level considered was P<0.05. The data were analyzed by SAS statistical software.
Among the 44 R. equi isolates evaluated, none was resistant for antimicrobials tested. All isolates were sensitive against AZN and CLR, with media MIC value of 0.49µg ml -1 and 0.11µg ml -1 , respectively. However, 27% (12/44) of R. equi isolates were classified as intermediate sensitivity for ERY, with media MIC value of 0.54µg ml -1 . This result for ERY can be explained by its use in combination with rifampin as treatment of choice since the 1980s (GIGUÈRE et al., 2011) . Probably, this profile could be worse if rifampin was not used, since this combination reduces the likelihood of R. equi resistance to either drug (PRESCOTT & NICHOLSON, 1984) . It is noteworthy that ERY resistance can drive to AZN and CLR resistance. The molecular mechanisms of macrolide resistance of R. equi isolates have not been determined, but it is known that cross-resistance among macrolides is common (GIGUÈRE et al., 2011; MUSCATELLO, 2012) ; thus if an isolate is resistant to ERY probably will be also resistant to AZM and CLR.
BUCKLEY et al. (2007) (GIGUÈRE et al., 2010) . Differently, in this study it was not observed significant increase in the MIC values for isolates collected from 1991 to 2013 (P>0.05). This finding can be associated with the mass macrolide treatment of foals with subclinical pulmonary lesions and, especially, the antimicrobial chemoprophylaxis against R. equi foal pneumonia, common in other countries (GIGUÈRE et al., 2011; MUSCATELLO, 2011) . However, for CLR, the clinical samples showed the major MIC values when compare with R. equi isolates from feces, soil and installations samples (P<0.05). This result is according to selection pressure hypothesis, since rhodococcosis is a chronic disease and repeated treatment can easily target to macrolide resistance (GIGUÈRE et al., 2010) . RIBEIRO et al. (2006) demonstrated strong efficacy of AZM against Brazilian R. equi isolates (MIC 90 <1.5µg ml -1 ). Similarly, in the present study, it was observed MIC 90 values between 0.5 and 1µg ml -1 , reinforcing the effectiveness of AZM in Brazilian isolates. Our results corroborate with MIC values observed by others studies, despite the timing among the publications to be more than 10 years (JACKS et al., 2003; CARLSON et al., 2010; RIESENBERG et al., 2013) (Table 1) Although in other countries R. equi macrolide resistance appears to be in a more advanced step, R. equi Brazilian isolates used here showed a large susceptibility profile, except against ERY, for which it was observed some resistance evidence due the intermediate sensitivity profile verified. In order to avoid this process, since the antimicrobials evaluated herein are the best rhodococcosis treatment options, it was highlighted the importance of microbiological culture and R. equi antimicrobial susceptibility testing in vitro before beginning treatment. Table 1 -Minimum inhibitory concentration (MIC) of three antimicrobial agents against R. equi Brazilian isolates from clinical (n=15), feces (n=9), installations (n=5) and soil (n=15) samples. * MIC50 and MIC90 were defined as the lowest concentrations of antimicrobials capable of inhibiting the growth of 50% and 90% of isolates, respectively. ATM=antimicrobial, SP=susceptibility profile, S=sensitivity, IS=intermediate sensitivity and R=resistance. S: =2µg ml -1 (AZM and CLR) and =0.5µg/ml (ERY); R: =8µg ml -1 (AZM, CLR and ERY), IS: MIC values between the concentrations mentioned (breakpoints according to CLSI, 2009 ).
